Related Experiment Videos
High density lipoproteins, genetic polymorphism for apo A-I and coronary artery disease
L A Simons1, S Balasubramaniam, A Szanto
1Lipid Research Department, St Vincent's Hospital, Sydney, NSW, Australia.
Insights
The P2 allele, a genetic marker near the apo A-I gene, is not significantly associated with coronary artery disease (CAD) in an Australian population. This study found no link between the P2 allele and CAD presence.
Area of Science:
- Cardiovascular Genetics
- Molecular Epidemiology
Background:
- High-density lipoprotein (HDL) cholesterol and apolipoprotein A-I (apo A-I) are established risk factors for coronary artery disease (CAD).
- A specific genetic polymorphism, the PstI site polymorphism (P2) near the apo A-I gene, has been controversially linked to CAD development.
Purpose of the Study:
- To investigate the association between the rare P2 allele and coronary artery disease (CAD) in an Australian population.
- To clarify the controversial relationship between the P2 allele and CAD risk.
Main Methods:
- A case control study design was employed.
- Data included 159 individuals with angiographically confirmed CAD and 99 healthy controls.
- Multiple logistic regression analysis was used, adjusting for relevant covariates.
Main Results:
- The prevalence of the P2 allele did not significantly differ between CAD cases (11%) and controls (9%).
- The P2 allele was not a significant predictor of CAD in the logistic regression model (odds ratio 1.83; 95% confidence interval 0.65-5.19).
Conclusions:
- The rare P2 allele is not significantly associated with coronary artery disease (CAD) in the studied Australian population.
- The findings do not support a role for the P2 allele as an independent risk factor for CAD.
Abstract:
HDL cholesterol and apolipoprotein A-I are associated with the development of coronary artery disease (CAD). The presence of a PstI site polymorphism adjacent to the gene encoding apo A-I (known as P2) has also been shown to be associated with CAD but this relationship is controversial. A case control study was conducted in an Australian population to re-examine whether the rare P2 allele is associated with CAD. Data were derived from 159 cases of angiographically confirmed CAD and 99 healthy controls. The proportion of CAD cases carrying the P2 allele did not differ significantly from controls (11% versus 9%). In a multiple logistic regression model controlling for the effects of age, country of birth, hypertension and hypotensive drugs, body mass index and lipid variables, the P2 allele failed to predict significantly the presence of CAD (odds ratio 1.83; 95% confidence interval 0.65-5.19).